Pantera Bio
Last verified 2026-06-12. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $100.4Mattributed |
|---|---|
| Latest round | series-a, $100.4M, 2024-01-01attributed |
| Founded | 2020 |
| Headquarters | Mol, Belgium |
| Industry | bio |
| Stage | series-a |
| Website | panterabio.com |
Pantera Bio is a clinical-stage biotech developing first-in-class small molecules that target the tumor microenvironment to reinvigorate exhausted immune cells in solid tumors. Its compounds work through a mechanism distinct from checkpoint inhibitors, giving it an opportunity in patients who have progressed on PD-1 therapy.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-01-01 | series-a | $100.4M | undisclosed |
Detected tech stack
unknown
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $100.4M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $100.4M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | panterabio.com, read 2026-06-12 |
| Description | self-reported | panterabio.com, read 2026-06-12 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.